FDA Approves Treosulfan With Fludarabine as a Preparative Regimen for alloHSCT in Adult and Pediatric Patients with AML or MDS

On January 21, the US Food and Drug Administration (FDA) approved treosulfan, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome.

For more information, read the FDA Announcement or the Medexus press release.

Posted on 2/7/2025